MedPage Today -- The everolimus-eluting Xience stent appears superior to the paclitaxel-eluting Taxus stent based on the clinical endpoint of target lesion failure, according to findings from the SPIRIT-IV trial.
MedPage Today -- The everolimus-eluting Xience stent appears superior to the paclitaxel-eluting Taxus stent based on the clinical endpoint of target lesion failure, according to findings from the SPIRIT-IV trial.
